Trial Profile
A Phase I, Randomized, Subject and Investigator-Blind, Sponsor Open, Multiple Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2019
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 07 Jun 2011 Actual initiation date changed from Dec 2010 to Nov 2010 and trial location (Singapore) identified as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.